Drugs / GSK323527A
last change Oct 2006 re-read 2 minutes ago

GSK323527A

Developed for
diphtheria · haemophilus infectious disease · hepatitis B virus infection · tetanus
Investigated by
GlaxoSmithKline

Trials 1 · a red edge is where a trial was stopped

2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 3 NCT00332566 Jun → Oct 2006 diphtheria, haemophilus infectious disease, hepatitis B virus infection, tetanus GlaxoSmithKline Completed No outcome recorded

Evidence & citations 1 cited value

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as GSK323527A ClinicalTrials.gov intervention name — accepted as the source's own label NCT00332566